POST Online Media Lite Edition



 

FTC says Danaher Corporation’s acquisition of GE Biopharma anticompetitive

Christian Fernsby |
The Federal Trade Commission has approved a final order settling charges that Danaher Corporation’s acquisition of GE Biopharma would likely reduce competition in highly concentrated markets that supply biopharmaceutical companies with key inputs.

Article continues below



Topics: FTC    DANAHER CORPORATION    GE BIOPHARMA   

Danaher is divesting to Sartorius AG all rights and assets to research, develop, manufacture, market, and sell these products. Based in Germany, Sartorius provides bioprocessing equipment and other products to the life sciences industry.

The products to be divested include: microcarrier beads, conventional low-pressure liquid chromatography columns, conventional low-pressure liquid chromatography skids, single-use low pressure liquid chromatography skids, chromatography resins, low-pressure liquid chromatography continuous chromatography systems, single-use tangential flow filtration systems, and label-free molecular characterization instruments.


What to read next

Tronox to vigorously fight FTC lawsuit against Cristal acquisition
Danaher completes acquisition of Pall Corporation
Danaher to buy Pall in $13.8 billion transaction